Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CFO Sandip Kapadia Sells 1,775 Shares of Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CFO Sandip Kapadia sold 1,775 shares of the stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $38.05, for a total transaction of $67,538.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Sandip Kapadia also recently made the following trade(s):

• On Tuesday, January 21st, Sandip Kapadia sold 25,000 shares of Harmony Biosciences stock. The shares were sold at an average price of $40.18, for a total value of $1,004,500.00.

Harmony Biosciences Price Performance

Shares of HRMY opened at $38.42 on Wednesday. The company has a market cap of $2.19 billion, a P/E ratio of 18.21, a PEG ratio of 0.51 and a beta of 0.78. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $28.14 and a fifty-two week high of $41.61. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. The firm’s 50 day moving average price is $35.08 and its 200 day moving average price is $35.19.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. The business had revenue of $186.00 million for the quarter, compared to analyst estimates of $184.07 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The company’s revenue was up 16.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.63 earnings per share. On average, research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Harmony Biosciences

Several large investors have recently bought and sold shares of HRMY. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Harmony Biosciences by 21.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company’s stock valued at $80,000 after buying an additional 360 shares during the period. GAMMA Investing LLC raised its holdings in Harmony Biosciences by 92.6% in the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after acquiring an additional 436 shares in the last quarter. CWM LLC lifted its stake in Harmony Biosciences by 111.7% in the third quarter. CWM LLC now owns 1,469 shares of the company’s stock worth $59,000 after acquiring an additional 775 shares during the last quarter. KBC Group NV grew its holdings in Harmony Biosciences by 79.9% during the 4th quarter. KBC Group NV now owns 1,844 shares of the company’s stock worth $63,000 after acquiring an additional 819 shares in the last quarter. Finally, Hedeker Wealth LLC increased its position in shares of Harmony Biosciences by 1.2% in the 4th quarter. Hedeker Wealth LLC now owns 76,203 shares of the company’s stock valued at $2,622,000 after purchasing an additional 916 shares during the last quarter. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Raymond James restated an “outperform” rating and issued a $40.00 target price on shares of Harmony Biosciences in a research report on Thursday, October 10th. Needham & Company LLC reaffirmed a “buy” rating and issued a $52.00 target price on shares of Harmony Biosciences in a research report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and set a $75.00 price target on shares of Harmony Biosciences in a research report on Monday. Cantor Fitzgerald upped their price objective on shares of Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $59.00 price objective (up previously from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $55.00.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.